Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1

Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms

(2017) Kenichi Suda et al.   Expert Review of Anticancer Therapy

Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression

(2017) Jinrong Liao et al.   Scientific Reports

miR-29b Mediates NF-κB Signaling in KRAS-Induced Non–Small Cell Lung Cancers

(2016) Stephanie Langsch et al.   CANCER RESEARCH

miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway

(2016) JING HAN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells

(2016) Weihua Zhang et al.   JOURNAL OF DRUG TARGETING

Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway

(2016) Pengfei Ma et al.   Theranostics

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

(2015) Chee-Seng Tan et al.   LANCET ONCOLOGY

Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer

(2014) E. C. de Bruin et al.   Cancer Discovery

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer

(2013) Bing Li et al.   LUNG CANCER

EGFR Mutations and Lung Cancer

(2011) Gilda da Cunha Santos et al.   Annual Review of Pathology-Mechanisms of Disease

Non-small-cell lung cancer

(2011) Peter Goldstraw et al.   LANCET

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1

(2009) Hilde Brems et al.   LANCET ONCOLOGY

The Role of MET Activation in Determining the Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2009) J. K. Rho et al.   MOLECULAR CANCER RESEARCH

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story

(2007) Lecia V. Sequist et al.   Annual Review of Medicine